PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.\', \'Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical, Cambridge, United Kingdom.\', \'Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2020.01991
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 32903476
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
?:title
  • The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32903476>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32903476>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all